<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797650</url>
  </required_header>
  <id_info>
    <org_study_id>CP543.3002</org_study_id>
    <secondary_id>2021-000387-30</secondary_id>
    <nct_id>NCT04797650</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2)</brief_title>
  <acronym>THRIVE-AA2</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an&#xD;
      investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or&#xD;
      greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering&#xD;
      the study will not receive active study drug but will receive tablets with no active&#xD;
      ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors,&#xD;
      the staff, and the patients will not know whether a patient is on active study drug (or the&#xD;
      dose) or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving an absolute Severity of Alopecia Tool (SALT) score ≤20</measure>
    <time_frame>Week 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;satisfied&quot; or &quot;very satisfied&quot;) on the Hair Satisfaction Patient Reported Outcome (SPRO)</measure>
    <time_frame>Week 24</time_frame>
    <description>SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving an absolute SALT score of ≤20</measure>
    <time_frame>Weeks 12, 16, and 20</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in SALT scores from Baseline</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the CGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Improvement (CGI-I) is a questionnaire that asks the clinician to evaluate the improvement or worsening of the patient's alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the PGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) is a self-administered questionnaire that asks the patient to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the CGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Severity (CGI-S) is a questionnaire that asks the clinician to evaluate the severity of the patient's alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Severity (PGI-S) is a self-administered questionnaire that asks the patient to evaluate the severity of their alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 75% relative reduction in SALT score from Baseline</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 90% relative reduction in SALT score from Baseline</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on an eyebrow score</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>A clinician-rated scale that assesses the total eyebrow hair present. The score is derived by assessment of density and surface area of the patient's eyebrows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on an eyelash score</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>A clinician-rated scale that assesses the total eyelash hair present. The score is derived by assessment of density and distribution of the patient's eyelashes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;satisfied&quot; or &quot;very satisfied&quot;) on the Hair Satisfaction Patient Reported Outcome scale</measure>
    <time_frame>Weeks 12, 16, and 20</time_frame>
    <description>SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the individual items of the Hair Quality Patient Reported Outcome (QPRO) scale</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the depression scale of the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Week 24</time_frame>
    <description>HADS is a 14-item measure designed to assess anxiety and depression symptoms in medical patients. Items are rated on a 4-point severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the anxiety scale of the Hospital Anxiety and Depression Scale</measure>
    <time_frame>Week 24</time_frame>
    <description>HADS is a 14-item measure designed to assess anxiety and depression symptoms in medical patients. Items are rated on a 4-point severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving an absolute SALT score of ≤10</measure>
    <time_frame>Week 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>CTP-543, 8 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-543, 12 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543, 8 mg BID</intervention_name>
    <description>8 mg twice-daily (BID)</description>
    <arm_group_label>CTP-543, 8 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543, 12 mg BID</intervention_name>
    <description>12 mg twice-daily (BID)</description>
    <arm_group_label>CTP-543, 12 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, BID</intervention_name>
    <description>Placebo, twice-daily (BID)</description>
    <arm_group_label>Placebo, BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical presentation compatible with alopecia areata with a current episode lasting&#xD;
             at least 6 months and not exceeding 10 years at the time of Screening. Total disease&#xD;
             duration greater than 10 years is permitted.&#xD;
&#xD;
          -  At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and&#xD;
             Baseline.&#xD;
&#xD;
          -  Willing to comply with the study visits and requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with other medications or agents within 1 month of Baseline or during the&#xD;
             study that may affect hair regrowth or immune response.&#xD;
&#xD;
          -  Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical&#xD;
             treatment to the scalp, significant trauma to the scalp, or other scalp condition that&#xD;
             may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the&#xD;
             body at Screening and/or Baseline.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 3 months of Screening or&#xD;
             during the study, or biologics within 6 months of Screening or during the study.&#xD;
&#xD;
          -  Females who are nursing, pregnant, or planning to become pregnant while in the study,&#xD;
             and for 30 days after last dose of study drug.&#xD;
&#xD;
          -  Clinically significant medical condition, psychiatric disease, or social condition, as&#xD;
             determined by the Investigator, that may unfavorably alter the risk-benefit of study&#xD;
             participation, adversely affect study compliance, or confound interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Colleen E. Hamilton, MS</last_name>
    <phone>781-860-0045</phone>
    <email>AAclinicaltrial_inquiries@concertpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alliance Dermatology &amp; Mohs Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Floridian Research Institute LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MetroBoston Clinical Partners, LLC</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galen Research</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivida Dermatology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Dermatology Group P.C.</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Department of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Southwest Ohio</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Providence</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Texas Center for Clinical Research</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elixir Research Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research/Gateway</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research/Swinyer-Woseth Dermatology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jordan Valley Dermatology Center</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Rector and Visitors of the University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Care Clinic Ltd.</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 4N7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Quebec</city>
        <zip>G1W4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec Metropolitan</name>
      <address>
        <city>Quebec</city>
        <zip>L4B1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice - Hôpital Archet 2</name>
      <address>
        <city>Nice</city>
        <state>Alpes-maritimes</state>
        <zip>06202 CEDEX 3</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chru de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finestère</state>
        <zip>29609 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie</name>
      <address>
        <city>Frankfurt am main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim - Dermatologische Studienambulanz</name>
      <address>
        <city>Bad Bentheim</city>
        <state>Niedersachsen</state>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologische Studienambulanz</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinikai Központ, Bőr-, Nemikórtani És Onkodermatológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szte Áok Szent-Györgyi Albert Klinikai Központ Bőrgyógyászati És Allergológiai Klinika</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád-csanád</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bugát Pál Kórház</name>
      <address>
        <city>Gyöngyös</city>
        <state>Heves</state>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, Általános Orvostudományi Kar, Bőr-, Nemikórtani És Bőronkológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wromedica I. Bielicka, A. Strzalkowska S.C.</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>50-685</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sól</name>
      <address>
        <city>Nowa Sól</city>
        <state>Lubuskie</state>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Etg Siedlce</name>
      <address>
        <city>Siedlce</city>
        <state>Mazowieckie</state>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ot.Co Clinic Klinika Osipowicz &amp; Turkowski Sp. Z O.O.</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-716</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rcmed Oddzial Warszawa</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-892</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carpe Diem Centrum Medycyny Estetycznej</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-664</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Etg Warszawa</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-793</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Etg Skierniewice</name>
      <address>
        <city>Skierniewice</city>
        <state>Łódzkie</state>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón Y Cajal - Edificio Consultas Externas</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28081</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alopecia</keyword>
  <keyword>Hair loss</keyword>
  <keyword>Hair disease</keyword>
  <keyword>CTP-543</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

